Alexandre Bazinet

Sep 4, 2024 | digitalcommons.library.tmc.edu | Alexandre Bazinet |Tapan M Kadia |Nicholas Short |Gautam Borthakur

AbstractAcute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment (Rx) intensity may not be a key predictor of outcomes, assuming that an optimal response to therapy is achieved.

Mar 4, 2024 | thelancet.com | Alexandre Bazinet |Guillermo Garcia-Manero |Nicholas Short |Yesid Reyes Alvarado

Summary Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727 plus venetoclax.